10-K: GRI Bio, Inc. Files 10-K Report, Outlines Clinical Progress and Financial Position

GRI Bio, Inc. released its 10-K filing, detailing clinical trial advancements for GRI-0621 and GRI-0803, alongside its financial status and future funding needs.

Summary

• GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on therapies for inflammatory, fibrotic, and autoimmune disorders.
• The company's lead candidate, GRI-0621, is being developed for idiopathic pulmonary fibrosis (IPF), a severe lung disease affecting approximately 140,000 people in the U.S.
• GRI-0621 is an oral formulation of tazarotene, previously approved for topical use, and has been tested in over 1,700 patients.
• A Phase 2a biomarker study for GRI-0621 in IPF commenced in December 2023, with topline results expected in the second half of 2024.
• GRI-0803, another product candidate, is being developed for autoimmune disorders like lupus and multiple sclerosis, with a Phase 1a/1b trial planned for the first half of 2024.
• The company has a library of over 500 compounds acquired from JADO Technologies GmbH, designed to mimic the structure and function of GRI-0124.
• GRI Bio has incurred a net loss of $13.0 million in 2023 and $3.2 million in 2022, with an accumulated deficit of $31.5 million as of December 31, 2023.
• The company's cash and cash equivalents totaled $1.8 million as of December 31, 2023, which is expected to fund operations into the second half of 2024.
• GRI Bio completed a public offering in February 2024, raising $5.5 million in gross proceeds.
• The company is seeking additional funding to continue operations and regain compliance with Nasdaq listing requirements.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern if additional financing is not secured.

Sentiment

Score: 4

Explanation: The document highlights promising clinical developments but is overshadowed by significant financial challenges and going concern doubts. The need for additional capital and the risk of delisting from Nasdaq create a negative outlook.

Positives

• GRI-0621 has shown to be well-tolerated and to inhibit iNKT cell activity in preliminary trials.
• GRI-0803 has shown therapeutic benefit in multiple models of autoimmunity.
• The company has retained global development and commercialization rights to all product candidates.
• The company has a strong leadership team with experience in NKT cell research and drug development.
• The company has a library of over 500 novel compounds.

Negatives

• The company has incurred significant net losses since inception and expects to continue to incur losses.
• The company has limited operating history and is a small developing company.
• The company will require substantial additional capital to fund its operations.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company's stock price is expected to be highly volatile.
• The company's stock does not currently comply with Nasdaq listing rules.

Risks

• The company's business is highly dependent on the success of its lead product candidate, GRI-0621.
• Clinical development involves a lengthy, complex, and expensive process with an uncertain outcome.
• The company relies on third parties to conduct clinical trials and manufacture product candidates.
• The company may be unable to adequately protect its information systems from cyberattacks.
• The company may be unable to obtain additional capital on acceptable terms, or at all.
• The company may be delisted from The Nasdaq Capital Market.

Future Outlook

The company expects to continue to incur significant losses and will require substantial additional funding to continue operations and advance its clinical programs. Topline data from the Phase 2a trial for GRI-0621 is expected in the second half of 2024. The company plans to file an IND for a Phase 1a/1b trial of GRI-0803 in the first half of 2024.

Management Comments

• The company's goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
• The company believes that GRI-0621 may have the ability to become the first true disease-modifying therapy for IPF patients.
• The company intends to expand its leadership as a company dedicated to developing therapies that directly target the biological processes driving dysregulated immune responses.

Industry Context

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. GRI Bio faces competition from large companies with significant financial resources, as well as smaller companies with significant resources, in the development of products for the treatment of conditions GRI is also targeting, including IPF, SLE, MS, UC, PSC and NASH.

Comparison to Industry Standards

• GRI Bio is competing with large pharmaceutical companies such as AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis in the IPF market.
• In the SLE market, GRI Bio is competing with companies such as Astellas Pharma, AstraZeneca, Aurinia Pharmaceuticals, Biogen, GlaxoSmithKline, Johnson & Johnson, Nektar Therapeutics, Roche Holding, and Sanofi SA.
• The company is also competing with numerous companies in the PSC and NASH markets, including Albireo Pharma, Gilead Sciences, and Novo Nordisk.
• GRI Bio's approach of targeting NKT cells is unique, as no other companies are currently in clinical development targeting NKT cells as a method of treating these conditions.
• Current IPF therapies, such as nintedanib and pirfenidone, have limitations, including significant side effects and lack of improvement in overall survival, which GRI Bio aims to address with GRI-0621.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a convertible note and warrant purchase agreement with TEP Biotech, LLC in November 2018, which was subsequently amended and converted into common stock.
• The company entered into securities purchase agreements, senior secured notes, the Equity Warrants and the Exchange Warrants with Altium Growth Fund L.P.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances and potential loss of investment value due to the company's financial challenges.
• Employees may be affected by potential reductions in spending, layoffs, or changes in compensation.
• Customers and patients may benefit from the development of new therapies, but face uncertainty due to the company's financial instability.
• Suppliers and creditors may face the risk of delayed payments or non-payment if the company's financial situation worsens.

Next Steps

• The company plans to continue the Phase 2a trial for GRI-0621 in IPF.
• The company plans to file an IND for a Phase 1a/1b trial of GRI-0803 in the first half of 2024.
• The company will continue to evaluate indications for GRI-0621 and GRI-0803.
• The company will seek additional funding to continue operations and regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

GRI Bio, GRI-0621, GRI-0803, idiopathic pulmonary fibrosis, IPF, lupus, multiple sclerosis, NKT cells, clinical trials, biopharmaceutical, autoimmune disorders, fibrotic diseases, tazarotene, capital raise